Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 261

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

Open access
Brada, M., Viviers, L., Abson, C., Hines, F., Britton, J., Ashley, S., Sardell, S., Traish, D., Gonsalves, A., Wilkins, P., Westbury, C.·2003·Annals of Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdg371

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

    Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 1×

    “The 35% response rate in WHO grade III astrocytoma (anaplastic astrocytoma) [5] in comparison with a 6–8% response rate in grade IV tumours (glioblastoma multiforme) [6, 7] suggests a possible trend of increasing efficacy in lower grade tumours previously noted for nitrosourea-containing chemotherapy [8].”
    ResultSelf-citation
  • Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

    Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372 · cited 2×

    “The 35% response rate in WHO grade III astrocytoma (anaplastic astrocytoma) [5] in comparison with a 6–8% response rate in grade IV tumours (glioblastoma multiforme) [6, 7] suggests a possible trend of increasing efficacy in lower grade tumours previously noted for nitrosourea-containing chemotherapy [8].”
    MethodResultSelf-citation

Show all 2 references

Cited by

See all 261

Metadata

Authors
Brada, M., Viviers, L., Abson, C., Hines, F., Britton, J., Ashley, S., Sardell, S., Traish, D., Gonsalves, A., Wilkins, P., & Westbury, C.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2003-12
Volume
14
Issue
12
Pages
1715-1721
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2171212160
Cited by
261
References
2
FWCI
7.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. https://app.cochat.ai/papers/10.1093/annonc/mdg371
The paper
Brada, M., Viviers, L., Abson, C., Hines, F., Britton, J., Ashley, S., Sardell, S., Traish, D., Gonsalves, A., Wilkins, P., & Westbury, C. (2003). Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Annals of Oncology. https://doi.org/10.1093/annonc/mdg371

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.